标题
Proteasome inhibitors in acute leukemia
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 13, Issue 3, Pages 327-337
出版商
Informa UK Limited
发表日期
2013-03-12
DOI
10.1586/era.13.4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
- (2012) Eva Maria Huber et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Proteasome inhibitors in multiple myeloma: 10 years later
- (2012) P. Moreau et al. BLOOD
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
- (2012) W. Blum et al. BLOOD
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
- (2012) Y. H. Messinger et al. BLOOD
- Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
- (2012) C.-H. Pui et al. BLOOD
- Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
- (2012) Alexei F. Kisselev et al. CHEMISTRY & BIOLOGY
- A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
- (2012) Elisa Gallerani et al. EUROPEAN JOURNAL OF CANCER
- Pediatric acute myeloid leukemia
- (2012) Gertjan JL Kaspers Expert Review of Anticancer Therapy
- Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance
- (2012) Andrew J. Kale et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells
- (2012) Danian Nie et al. LEUKEMIA & LYMPHOMA
- CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
- (2012) Eric Sanchez et al. LEUKEMIA RESEARCH
- The Immunoproteasome as a Target in Hematologic Malignancies
- (2012) Deborah J. Kuhn et al. SEMINARS IN HEMATOLOGY
- Bacterial Self-Resistance to the Natural Proteasome Inhibitor Salinosporamide A
- (2011) Andrew J. Kale et al. ACS Chemical Biology
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase
- (2011) Fabio P.S. Santos et al. Clinical Lymphoma Myeloma & Leukemia
- Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen
- (2011) Lü Shuqing et al. EXPERIMENTAL HEMATOLOGY
- Novel Proteasome Inhibitors to Overcome Bortezomib Resistance
- (2011) Amy M. Ruschak et al. JNCI-Journal of the National Cancer Institute
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
- (2011) N E Franke et al. LEUKEMIA
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
- (2011) Jacob P Laubach et al. Expert Review of Hematology
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia
- (2010) A. M. Roccaro et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
- (2010) Ajita V. Singh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress
- (2010) Ulrike Seifert et al. CELL
- Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
- (2010) J. J. Wright CLINICAL CANCER RESEARCH
- Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance
- (2010) Xiaoming Li et al. JNCI-Journal of the National Cancer Institute
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
- (2010) Stephanie Markovina et al. Molecular Cancer
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
- (2009) D. Chauhan et al. BLOOD
- The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
- (2009) G. Bianchi et al. BLOOD
- Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
- (2009) F. Parlati et al. BLOOD
- The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan
- (2009) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
- (2009) Tony Muchamuel et al. NATURE MEDICINE
- Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
- (2008) E. C. Attar et al. CLINICAL CANCER RESEARCH
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
- (2008) R. Z. Orlowski et al. CLINICAL CANCER RESEARCH
- Mechanisms of proteasome inhibitor action and resistance in cancer
- (2008) David J. McConkey et al. DRUG RESISTANCE UPDATES
- Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells
- (2008) S. Markovina et al. MOLECULAR CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started